Mutations of the epidermal growth factor receptor (EGFR) have been proven to predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib. Although the "common" EGFR mutations, such as the L858R point mutation in exon 21 and the in-frame deletional mutation in exon 19, have been definitively associated with response to EGFR-TKIs, the correlation with response to treatment for many other rarer mutations is still unclear. In this study, we report the results of treating patients with advanced non-small cell lung cancer harboring rare EGFR mutations treated with EGFR-TKIs

Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations / T. De Pas, F. Toffalorio, M. Manzotti, C. Fumagalli, G. Spitaleri, C. Catania, A. Delmonte, M. Giovannini, L. Spaggiari, F. de Braud, M. Barberis. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - 6:11(2011 Nov), pp. 1895-1901.

Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations

C. Fumagalli;L. Spaggiari;F. de Braud;
2011

Abstract

Mutations of the epidermal growth factor receptor (EGFR) have been proven to predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib. Although the "common" EGFR mutations, such as the L858R point mutation in exon 21 and the in-frame deletional mutation in exon 19, have been definitively associated with response to EGFR-TKIs, the correlation with response to treatment for many other rarer mutations is still unclear. In this study, we report the results of treating patients with advanced non-small cell lung cancer harboring rare EGFR mutations treated with EGFR-TKIs
review literature as Topic ; neoplasm staging ; receptor, epidermal growth factor ; humans ; retrospective studies ; aged ; quinazolines ; aged, 80 and over ; lung neoplasms ; adult ; treatment outcome ; antineoplastic combined chemotherapy protocols ; middle aged ; adenocarcinoma ; carcinoma, non-small-cell lung ; mutation ; female ; male
Settore MED/06 - Oncologia Medica
Settore MED/21 - Chirurgia Toracica
nov-2011
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/175230
Citazioni
  • ???jsp.display-item.citation.pmc??? 47
  • Scopus 119
  • ???jsp.display-item.citation.isi??? 109
social impact